Skip to main content
SpringerLink
Log in

Evaluating Strategies for Combining Pharmacotherapy with Cognitive Behavioral Therapy

  • Chapter
Book cover The Massachusetts General Hospital Handbook of Cognitive Behavioral Therapy

Part of the book series: Current Clinical Psychiatry ((CCPSY))

  • 4485 Accesses

Abstract

This chapter provides an overview of the rationale for combining cognitive-behavioral therapies and pharmacologic treatments. Relevant research literature is presented across a range of disorders including anxiety and related disorders, mood disorders, eating disorders, schizophrenia, and substance use disorders. In addition, practical considerations are discussed related to how the combination approach may be utilized and applied in clinical practice including a case example to highlight how a combination approach may be completed successfully in a clinical setting. Finally, novel treatment approaches are discussed as a means of highlighting future directions for the use of combined treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Forand NR, DeRubeis RJ, Amsterdam JD. Combining medication and psychotherapy in the treatment of major mental disorders. In: Lambert MJ, editor. Bergin and Garfield’s handbook of psychotherapy and behavior change. 6th ed. Hoboken, NJ: Wiley; 2013. p. 735–74.

    Google Scholar 

  2. Otto MW, Smits JAJ, Reese HE. Combined psychotherapy and pharmacotherapy for mood and anxiety disorders in adults: review and analysis. Clin Psychol Sci Pract. 2005;12(1):72–86.

    Article  Google Scholar 

  3. Canton J, Scott KM, Glue P. Optimal treatment of social phobia: systematic review and meta-analysis. Neuropsychiatr Dis Treat. 2012;8:203–15.

    PubMed Central  CAS  PubMed  Google Scholar 

  4. Davidson JRT, Foa EB, Huppert JD, Keefe F, Franklin M, Compton J, Zhao N, Connor K, Lynch TR, Kishore G. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch Gen Psychiatry. 2004;61:1005–13.

    Article  CAS  PubMed  Google Scholar 

  5. Haug TT, Blomhoff S, Hellstrøm K, Holme I, Humble M, Madsbu HP, Wold JE. Exposure therapy and sertraline in social phobia: 1-year follow-up of a randomised controlled trial. Br J Psychiatry. 2003;182:312–8.

    Article  PubMed  Google Scholar 

  6. Foa EB, Franklin ME, Moser J. Context in the clinic: how well do cognitive-behavioral therapies and medications work in combination? Biol Psychiatry. 2002;52(10):987–97.

    Article  PubMed  Google Scholar 

  7. Furukawa TA, Watanabe N, Churchill R. Psychotherapy plus antidepressant for panic disorder with or without agoraphobia: systematic review. Br J Psychiatry. 2006;188:305–12.

    Article  PubMed  Google Scholar 

  8. Otto MW, McHugh RK, Simon NM, Farach FJ, Worthington JJ, Pollack MH. Efficacy of CBT for benzodiazepine discontinuation in patients with panic disorder: further evaluation. Behav Res Ther. 2010;59:831–8.

    Google Scholar 

  9. Otto MW, Tolin DF, Simon NM, Pearlson GD, Basden S, Meunier SA, et al. The efficacy of d-cycloserine for enhancing response to cognitive behavior therapy for panic disorder. Biol Psychiatry. 2010;67:365–70.

    Article  CAS  PubMed  Google Scholar 

  10. Simon NM, Otto MW, Worthington JJ, Hoge EA, Thompson EH, Lebeau RT, Moshier SJ, Zalta AK, Pollack MH. Next-step strategies for panic disorder refractory to initial pharmacotherapy: a 3-phase randomized clinical trial. J Clin Psychiatry. 2009;70:1563–70.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Power KG, Simpson RJ, Swanson V, Wallace LA. A controlled comparison of cognitive-behaviour therapy, diazepam, and placebo, alone and in combination, for the treatment of generalised anxiety disorder. J Anxiety Disord. 1990;4(4):267–92.

    Article  Google Scholar 

  12. Crits-Christoph P, Newman MG, Rickels K, Gallop R, Gibbons MB, Hamilton JL, Ring-Kurtz S, Pastva AM. Combined medication and cognitive therapy for generalized anxiety disorder. J Anxiety Disord. 2011;25:1087–94.

    Article  PubMed Central  PubMed  Google Scholar 

  13. Schneier FR, Neria Y, Pavlicova M, Hembree E, Suh EJ, Amsel L, Marshall RD. Combined prolonged exposure therapy and paroxetine for PTSD related to the World Trade Center attack: a randomized controlled trial. Am J Psychiatry. 2012;169(1):80–8.

    Article  PubMed Central  PubMed  Google Scholar 

  14. Rothbaum BO, Cahill SP, Foa EB, Davidson JR, Compton J, Connor KM, Astin MC, Hahn CG. Augmentation of sertraline with prolonged exposure in the treatment of posttraumatic stress disorder. J Traumatic Stress. 2006;19:625–38.

    Google Scholar 

  15. Simon NM, Connor KM, Lang AJ, Rauch S, Krulewicz S, LeBeau RT, Pollack MH. Paroxetine CR augmentation for posttraumatic stress disorder refractory to prolonged exposure therapy. J Clin Psychiatry. 2008;69(3):400–5.

    Article  PubMed  Google Scholar 

  16. van Minnen A, Arntz A, Keijsers GP. Prolonged exposure in patients with chronic PTSD: predictors of treatment outcome and dropout. Behav Res Ther. 2002;40(4):439–57.

    Article  PubMed  Google Scholar 

  17. Department of Veterans Affairs, Department of Defense. VA/DoD clinical practice guideline for management of post-traumatic stress disorder. 2010.

    Google Scholar 

  18. Rodrigues H, Figueira I, Gonçalves R, Mendlowicz M, Macedo T, Ventura P. CBT for pharmacotherapy non-remitters – a systematic review of a next-step strategy. J Affect Disord. 2011;129(1–3):219–28.

    Article  PubMed  Google Scholar 

  19. Keller MB, McCullough JP, Klein DN, Arnow B, Dunner DL, Gelenberg AJ, Zajecka J. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med. 2000;342(20):1462–70.

    Article  CAS  PubMed  Google Scholar 

  20. Manber R, Kraemer HC, Arnow BA, Trivedi MH, Rush AJ, Thase ME, Keller MB. Faster remission of chronic depression with combined psychotherapy and medication than with each therapy alone. J Consult Clin Psychol. 2008;76(3):459–67.

    Article  PubMed Central  PubMed  Google Scholar 

  21. Fava GA, Grandi S, Zielezny M, Canestrari R, Morphy MA. Cognitive behavioral treatment of residual symptoms in primary major depressive disorder. Am J Psychiatry. 1994;151(9):1295–9.

    Article  CAS  PubMed  Google Scholar 

  22. Thase ME, Friedman ES, Biggs MM, Wisniewski SR, Trivedi MH, Rush JA. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry. 2007;164(5):739–52.

    Article  PubMed  Google Scholar 

  23. National Institute for Health and Care Excellence. The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. Clinical guideline 38. London, UK: National Institute for Health and Care Excellence; 2006. www.nice.org.uk.

  24. Miklowitz DJ, Otto MW. Psychosocial interventions for bipolar disorder: a review of literature and introduction of the systematic treatment enhancement program. Psychopharmacol Bull. 2007;40(4):116–31.

    PubMed  Google Scholar 

  25. Scott J, Garland A, Moorhead S. A pilot study of cognitive therapy in bipolar disorders. Psychol Med. 2001;31(3):459–67.

    CAS  PubMed  Google Scholar 

  26. Ball JR, Mitchell PB, Corry JC, Skillecorn A, Smith M, Malhi GS. A randomized controlled trial of cognitive therapy for bipolar disorder: focus on long-term change. J Clin Psychiatry. 2006;67(2):277–86.

    Article  PubMed  Google Scholar 

  27. Scott J, Paykel E, Morriss R, Bentall R, Kinderman P, Johnson T, Hayhurst H. Cognitive-behavioural therapy for severe and recurrent bipolar disorders: randomised controlled trial. Br J Psychiatry. 2006;188:313–20.

    Article  PubMed  Google Scholar 

  28. National Institute for Health and Care Excellence. Core interventions in the treatment and management of schizophrenia in primary and secondary care (update). Clinical guideline 82. London, UK: National Institute for Health and Care Excellence; 2009. www.nice.org.uk.

  29. Schizophrenia Patient Outcomes Research Team. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull. 2010;36(1):94–103.

    Article  Google Scholar 

  30. Wykes T, Steel C, Everitt B, Tarrier N. Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. Schizophr Bull. 2008;34(3):523–37.

    Article  PubMed Central  PubMed  Google Scholar 

  31. Tarrier N, Wittkowski A, Kinney C, McCarthy E, Morris J, Humphreys L. Durability of the effects of cognitive-behavioural therapy in the treatment of chronic schizophrenia: 12-month follow-up. Br J Psychiatry. 1999;174:500–4.

    Article  CAS  PubMed  Google Scholar 

  32. Sensky T, Turkington D, Kingdon D, Scott JL, Scott J, Siddle R, Barnes TR. A randomized controlled trial of cognitive-behavioral therapy for persistent symptoms in schizophrenia resistant to medication. Arch Gen Psychiatry. 2000;57(2):165–72.

    Article  CAS  PubMed  Google Scholar 

  33. Bacaltchuk J, Hay P, Trefiglio R. Antidepressants versus psychological treatments and their combination for bulimia nervosa. Cochrane Database Syst Rev. 2001;2001(4), CD003391.

    Google Scholar 

  34. Whittal ML, Agras WS, Gould RA. Bulimia nervosa: a meta-analysis of psychosocial and pharmacological treatments. Behav Ther. 1999;30:117–35.

    Article  Google Scholar 

  35. Agras WS, Rossiter EM, Arnow B, Schneider JA, Telch CF, Raeburn SD, Koran LM. Pharmacologic and cognitive-behavioral treatment for bulimia nervosa: a controlled comparison. Am J Psychiatry. 1992;149:82–7.

    Article  CAS  PubMed  Google Scholar 

  36. Vocks S, Tuschen-Caffier B, Pietrowsky R, Rustenbach SJ, Kerstig A, Herpertz S. Meta-analysis of the effectiveness of psychological and pharmacological treatments for binge eating disorder. Int J Eat Disord. 2010;43(3):205–17.

    PubMed  Google Scholar 

  37. Grilo CM, Masheb RM, Wilson GT. Efficacy of cognitive behavioral therapy and fluoxetine for the treatment of binge eating disorder: a randomized double-blind placebo-controlled comparison. Biol Psychiatry. 2005;57:301–9.

    Article  CAS  PubMed  Google Scholar 

  38. Halmi KA, Agras WS, Crow S, Mitchell J, Wilson GT, Bryson SW, Kraemer HC. Predictors of treatment acceptance and completion in anorexia nervosa: implications for future study designs. Arch Gen Psychiatry. 2005;62(7):776–81.

    Article  PubMed  Google Scholar 

  39. Magill M, Ray LA. Cognitive-behavioral treatment with adult alcohol and illicit drug users: a meta-analysis of randomized controlled trials. J Stud Alcohol Drugs. 2009;70(4):516–27.

    Article  PubMed Central  PubMed  Google Scholar 

  40. Agosti V, Nunes EV, O’Shea D. Do manualized psychosocial interventions help reduce relapse among alcohol-dependent adults treated with naltrexone or placebo? A meta-analysis. Am J Addict. 2012;21(6):501–7.

    Article  PubMed  Google Scholar 

  41. Lam DH, Bright J, Jones S, Hayward P, Schuck N, Chisholm D, et al. Cognitive therapy for bipolar disorder: a pilot study of relapse prevention. Cognit Ther Res. 2000;24:503–20.

    Article  Google Scholar 

  42. Lam DH, Watkins ER, Hayward P, Bright J, Wright K, Kerr N, et al. A randomized controlled study of cognitive therapy for relapse prevention for bipolar affective disorder. Arch Gen Psychiatry. 2003;60:145–52.

    Article  PubMed  Google Scholar 

  43. Barker MJ, Greenwood KM, Jackson M, Crowe SF. Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs. 2004;18:37–48.

    Article  CAS  PubMed  Google Scholar 

  44. Ahmed M, Westra HA, Stewart SH. A self-help handout for benzodiazepine discontinuation using cognitive behavioral therapy. Cognit Behav Pract. 2008;15:317–24.

    Article  Google Scholar 

  45. Fava GA, Grandi S, Zielezny M, Rafanelli C, Canastrari R. Four year outcome for cognitive behavioral treatment of residual symptoms in major depression. Am J Psychiatry. 1996;153:945–7.

    Article  CAS  PubMed  Google Scholar 

  46. Fava GA, Rafanelli C, Grandi S, Canastrari R, Morphy MA. Six year outcome for cognitive behavioral treatment of residual symptoms in major depression. Am J Psychiatry. 1998;155:1443–5.

    Article  CAS  PubMed  Google Scholar 

  47. Otto MW, et al. Discontinuation of benzodiazepine treatment: efficacy of cognitive-behavior therapy for patients with panic disorder. Am J Psychiatry. 1993;150(10):1485–90.

    Google Scholar 

  48. Schmidt NB, Wollaway-Bickel K, Trakowski JH, Santiago HT, Vasey M. Antidepressant discontinuation in the context of cognitive behavioral treatment for panic disorder. Behav Res Ther. 2002;40:67–73.

    Google Scholar 

  49. Hofmann SG, Huweler R, MacKillop J, Kantak KM. Effects of d cycloserine on craving to alcohol cues in problem drinkers: preliminary findings. Am J Drug Alcohol Abuse. 2012;38:101–7.

    Article  PubMed  Google Scholar 

  50. Hofmann SG, Sawyer AT, Asnaani A. D-cycloserine as an augmentation strategy for cognitive behavioral therapy for anxiety disorders: an update. Curr Pharm Des. 2012;18:5659–62.

    Article  CAS  PubMed  Google Scholar 

  51. Hofmann SG, Smits JA, Rosenfield D, Simon N, Otto MW, Meuret AE, Marques L, Fang A, Tart C, Pollack MH. d-Cycloserine as an augmentation strategy with cognitive-behavioral therapy for social anxiety disorder. Am J Psychiatry. 2013;170:751–8.

    Article  PubMed Central  PubMed  Google Scholar 

  52. Hofmann SG, Fang A, Gutner CA. Cognitive enhancers for the treatment of anxiety disorders. Restor Neurol Neurosci. 2013.

    Google Scholar 

  53. Danysz W, Parsons CG. Glycine and N-methyl-d-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol Rev. 1998;50:597–664.

    CAS  PubMed  Google Scholar 

  54. Ressler KJ, Rothbaum BO, Tannenbaum L, et al. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry. 2004;61:1136–44.

    Article  PubMed  Google Scholar 

  55. Smits JA, Rosenfield D, Otto MW, Marques L, Davis ML, Meuret AE, Simon NM, Pollack MH, Hofmann SG. d-cycloserine enhancement of exposure therapy for social anxiety disorder depends on the success of exposure sessions. J Psychiatr Res. 2013;47:1455–61.

    Article  PubMed Central  PubMed  Google Scholar 

  56. Nave AM, Tolin DF, Stevens MC. Exposure therapy, d-cycloserine, and functional magnetic resonance imaging in patients with snake phobia: a randomized pilot study. J Clin Psychiatry. 2012;73:1179–86.

    Article  CAS  PubMed  Google Scholar 

  57. Wilhelm S, Buhlmann U, Tolin DF, Meunier SA, Pearlson GD, Reese HE, et al. Augmentation of behavior therapy with d-cycloserine for obsessive compulsive disorder. Am J Psychiatry. 2008;165:335–41.

    Article  PubMed  Google Scholar 

  58. Litz BT, Salters-Pedneault K, Steenkamp MM, Hermos JA, Bryant RA, Otto MW, et al. A randomized placebo-controlled trial of D-cycloserine and exposure therapy for posttraumatic stress disorder. J Psychiatr Res. 2012;46:1184–90.

    Article  PubMed  Google Scholar 

  59. Guastella AJ, Richardson R, Lovibond PF, Rapee RM, Gaston JE, Mitchell P, Dadds MR. A randomized controlled trial of d-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry. 2008;63:544–9.

    Article  CAS  PubMed  Google Scholar 

  60. Heresco-Levy U, Kremer I, Javitt DC, et al. Pilot-controlled trial of D cycloserine for the treatment of post-traumatic stress disorder. Int J Neuropsychopharmacol. 2002;5:301–7.

    Google Scholar 

  61. Gottlieb JD, Cather C, Shanahan M, Creedon T, Macklin EA, Goff DC. D-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia. Schizophr Res. 2011;131:69–74.

    Google Scholar 

  62. Kennedy AP, Gross RE, Whitfield N, Drexler KPG, Kilts CD. A controlled trial of the adjunct use of d-cycloserine to facilitate cognitive behavioral therapy outcomes in a cocaine-dependent population. Addict Behav. 2012;37:900–7.

    Google Scholar 

  63. Siegmund A, Golfels F, Finck C, Halisch A, Rath D, Plag J, et al. D closerine does not improve but might slightly speed up the outcome of in-vivo exposure therapy in patients with severe agoraphobia and panic disorder in a randomized double blind clinical trial. J Psychiatr Res. 2011;45:1042–7.

    Article  PubMed  Google Scholar 

Additional Resources

  1. Anxiety and Depression Association of America. Treatment http://www.adaa.org/living-with-anxiety/children/treatment.

  2. Association for Behavioral and Cognitive Therapies. Treatment options, CBT or medication? http://www.abct.org/Help/?m=mFindHelp&fa=CBT_Or_Medication.

  3. Otto MW, Simon NM, Olatunji BO, Sung SC, Pollack MH. 10-Minute CBT: integrating cognitive-behavioral strategies into your practice. Oxford: Oxford University Press; 2011.

    Google Scholar 

  4. National Institute of Mental Health Psychotherapies. http://www.nimh.nih.gov/health/topics/psychotherapies/index.shtml.

  5. Sudak SM. Combining CBT and medication: an evidence-based approach. Hoboken, NJ: Wiley; 2011.

    Book  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, Massachusetts General Hospital, One Bowdoin Square, 6th Floor, Boston, MA, 02114, USA

    Meredith E. Charney Ph.D. & Naomi M. Simon M.D., M.Sc.

  2. Harvard Medical School, Boston, MA, 02114, USA

    Meredith E. Charney Ph.D. & Naomi M. Simon M.D., M.Sc.

  3. Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, One Bowdoin Square, 6th Floor, Boston, MA, 02114, USA

    Amanda W. Calkins Ph.D.

  4. Harvard Medical School, Anxiety Disorders Center/Center for CBT, Institute of Living, 200 Retreat Avenue, Hartford, CT, 06106, USA

    Lauren S. Hallion Ph.D.

Authors
  1. Meredith E. Charney Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amanda W. Calkins Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lauren S. Hallion Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Naomi M. Simon M.D., M.Sc.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Meredith E. Charney Ph.D. .

Editor information

Editors and Affiliations

  1. Massachusetts General Hospital, Boston, Massachusetts, USA

    Timothy J. Petersen

  2. Cognitive-Behavioral Therapy Program, Massachusetts General Hospital, Boston, Massachusetts, USA

    Susan E. Sprich

  3. Simches Research Building, Massachusetts General Hospital, Boston, Massachusetts, USA

    Sabine Wilhelm

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Science+Business Media New York

About this chapter

Cite this chapter

Charney, M.E., Calkins, A.W., Hallion, L.S., Simon, N.M. (2016). Evaluating Strategies for Combining Pharmacotherapy with Cognitive Behavioral Therapy. In: Petersen, T., E. Sprich, S., Wilhelm, S. (eds) The Massachusetts General Hospital Handbook of Cognitive Behavioral Therapy. Current Clinical Psychiatry. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-2605-3_21

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-2605-3_21

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-2604-6

  • Online ISBN: 978-1-4939-2605-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation